Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease

British Journal of Pharmacology

Volumn 172, Issue 15, 2015, Pages 3714-3727

  Clark, I A ^a   Vissel, B ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; MICRORNA; MITOCHONDRIAL DNA; PROTEIN S 100; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; AUTACOID; BIOLACTIN; LACTIC ACID; PATHOGEN ASSOCIATED MOLECULAR PATTERN;

ALZHEIMER DISEASE; CHRONIC DISEASE; DAMAGE ASSOCIATED MOLECULAR PATTERN; HUMAN; INFLAMMATION; INNATE IMMUNITY; MICROCOSM; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGEN ASSOCIATED MOLECULAR PATTERN; POSTOPERATIVE COGNITIVE DYSFUNCTION; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; ANIMAL; GENETICS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; LACTIC ACID; PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES;

EID: 84937431574     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13181     Document Type: Review

References (210)

1. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, et al. (1985). Human tumor necrosis factor: production, purification, and characterization. J Biol Chem 260: 2345-2354.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Alexandrov PN, Dua P, Lukiw WJ, (2014). Up-regulation of miRNA-146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS. Front Neurol 5: 181.
5. Alleva LM, Yang H, Tracey KJ, Clark IA, (2005). High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria. Trans R Soc Trop Med Hyg 99: 171-175.
6. Alleva LM, Budd AC, Clark IA, (2008). Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol 181: 1454-1459.
7. Alvarez-Arellano L, Maldonado-Bernal C, (2014). Helicobacter pylori and neurological diseases: married by the laws of inflammation. World J Gastrointest Pathophysiol 5: 400-404.
8. Andersson U, Tracey KJ, (2003). HMGB1 in sepsis. Scand J Infect Dis 35: 577-584.
9. Andersson U, Wang HC, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. (2000). High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570.
10. Arsenijevic D, Girardier L, Seydoux J, Chang HR, Dulloo AG, (1997). Altered energy balance and cytokine gene expression in a murine model of chronic infection with Toxoplasma gondii. Am J Physiol 272: E908-E917.
11. Arvin B, Neville LF, Barone FC, Feuerstein GZ, (1996). The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 20: 445-452.
12. Bakulski KM, Dolinoy DC, Sartor MA, Paulson HL, Konen JR, Lieberman AP, et al. (2012). Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis 29: 571-588.
13. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, et al. (2005). The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25: 823-829.
14. Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, et al. (2002). Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 109: E31.
15. Bernardino L, Agasse F, Silva B, Ferreira R, Grade S, Malva JO, (2008). Tumor necrosis factor-alpha modulates survival, proliferation, and neuronal differentiation in neonatal subventricular zone cell cultures. Stem Cells 26: 2361-2371.
16. Beutler B, Milsark IW, Cerami AC, (1985). Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 229: 869-871.
17. Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, et al. (1993). Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome. Ann N Y Acad Sci 695: 91-102.
18. Bhutta ZA, Mansoorali N, Hussain R, (1997). Plasma cytokines in paediatric typhoidal salmonellosis: correlation with clinical course and outcome. J Infect 35: 253-256.
19. Bihaqi SW, Huang H, Wu J, Zawia NH, (2011). Infant exposure to lead (Pb) and epigenetic modifications in the aging primate brain: implications for Alzheimer's disease. J Alzheimers Dis 27: 819-833.
20. Bihaqi SW, Schumacher A, Maloney B, Lahiri DK, Zawia NH, (2012). Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer Res 9: 574-588.
21. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M, (1989). Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244-247.
22. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B, (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72: 3666-3670.
23. Carswell-Richards EA, Williamson BD, (2012). A man of vision and the discovery of tumor necrosis factor. Cancer Immun 12: 1-4.
24. Castellani RJ, Smith MA, (2011). Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J Pathol 224: 147-152.
25. Castello MA, Jeppson JD, Soriano S, (2014). Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease. BMC Neurol 14: 169.
26. Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, et al. (2012). Alarmins: awaiting a clinical response. J Clin Invest 122: 2711-2719.
27. Chavan SS, Huerta PT, Robbiati S, Valdes-Ferrer SI, Ochani M, Dancho M, et al. (2012). HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med 18: 930-937.
28. Cheng YJ, Yang BC, Liu MY, (2006). Lead increases lipopolysaccharide-induced liver-injury through tumor necrosis factor-alpha overexpression by monocytes/macrophages: role of protein kinase C and P42/44 mitogen-activated protein kinase. Environ Health Perspect 114: 507-513.
29. Chirila AM, Brown TE, Bishop RA, Bellono NW, Pucci FG, Kauer JA, (2014). Long-term potentiation of glycinergic synapses triggered by interleukin 1beta. Proc Natl Acad Sci U S A 111: 8263-8268.
30. Chiti F, Dobson CM, (2006). Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333-366.
31. Chiu SL, Cline HT, (2010). Insulin receptor signaling in the development of neuronal structure and function. Neural Dev 5: 7.
32. Chiu SL, Chen CM, Cline HT, (2008). Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 58: 708-719.
33. Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B, (2012). Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol Rev 64: 1004-1026.
34. Clark IA, (1979a). Protection of mice against Babesia microti with cord factor, COAM, zymosan, glucan, Salmonella and Listeria. Parasite Immunol 1: 179-196.
35. Clark IA, (1979b). Resistance to Babesia spp. and Plasmodium sp. in mice pretreated with an extract of Coxiella burnetii. Infect Immun 24: 319-325.
36. Clark IA, (1982). Suggested importance of monokines in pathophysiology of endotoxin shock and malaria. Klin Wochenschr 60: 756-758.
37. Clark IA, Cowden WB, (1989). Is TNF a key to acute infectious illness? Today's Life Sci 1: 26-29.
38. Clark IA, Vissel B, (2013). Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochem Pharmacol 86: 862-871.
39. Clark IA, Vissel B, (2014). Inflammation-sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflammation 11: 51.
40. Clark IA, Allison AC, Cox FE, (1976). Protection of mice against Babesia and Plasmodium with BCG. Nature 259: 309-311.
41. Clark IA, Cox FE, Allison AC, (1977). Protection of mice against Babesia spp. and Plasmodium spp. with killed Corynebacterium parvum. Parasitology 74: 9-18.
42. Clark IA, Virelizier J-L, Carswell EA, Wood PR, (1981). Possible importance of macrophage-derived mediators in acute malaria. Infect Immun 32: 1058-1066.
43. Clark IA, Alleva LM, Vissel B, (2010). The roles of TNF in brain dysfunction and disease. Pharmacol Ther 128: 519-548.
44. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. (2008). Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14: 27-41.
45. Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, et al. (2009). Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care 13: R174.
46. Coskun P, Wyrembak J, Schriner SE, Chen HW, Marciniack C, Laferla F, et al. (2012). A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta 1820: 553-564.
47. Cumiskey D, Butler MP, Moynagh PN, O'Connor JJ, (2007). Evidence for a role for the group I metabotropic glutamate receptor in the inhibitory effect of tumor necrosis factor-alpha on long-term potentiation. Brain Res 1136: 13-19.
48. Cunningham C, Maclullich AM, (2013). At the extreme end of the psychoneuroimmunological spectrum: delirium as a maladaptive sickness behaviour response. Brain Behav Immun 28: 1-13.
49. Desplats P, Spencer B, Coffee E, Patel P, Michael S, Patrick C, et al. (2011). Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem 286: 9031-9037.
50. Detrait ER, Danis B, Lamberty Y, Foerch P, (2014). Peripheral administration of an anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice. Neurochem Int 72: 10-13.
51. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370: 311-321.
52. Dunn N, Mullee M, Perry VH, Holmes C, (2005). Association between dementia and infectious disease: evidence from a case-control study. Alzheimer Dis Assoc Disord 19: 91-94.
53. Edwards MM, Robinson SR, (2006). TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease. J Neural Transm 113: 1709-1715.
54. Eikelenboom P, Veerhuis R, van Exel E, Hoozemans JJ, Rozemuller AJ, van Gool WA, (2011). The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 8: 142-150.
55. Emelyanov VV, (2001). Evolutionary relationship of Rickettsiae and mitochondria. FEBS Lett 501: 11-18.
56. Esiri MM, (2007). The interplay between inflammation and neurodegeneration in CNS disease. J Neuroimmunol 184: 4-16.
57. Fang P, Schachner M, Shen YQ, (2012). HMGB1 in development and diseases of the central nervous system. Mol Neurobiol 45: 499-506.
58. Ferguson AR, Christensen RN, Gensel JC, Miller BA, Sun F, Beattie EC, et al. (2008). Cell death after spinal cord injury is exacerbated by rapid TNFalpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane. J Neurosci 28: 11391-11400.
59. Fernandez JA, Rojo L, Kuljis RO, Maccioni RB, (2008). The damage signals hypothesis of Alzheimer's disease pathogenesis. J Alzheimers Dis 14: 329-333.
60. Foell D, Wittkowski H, Vogl T, Roth J, (2007). S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81: 28-37.
61. Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, et al. (2012). Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflammation 9: 99.
62. Gallucci S, Matzinger P, (2001). Danger signals: SOS to the immune system. Curr Opin Immunol 13: 114-119.
63. Gandy S, (2005). The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 115: 1121-1129.
64. Gardner RM, Nyland JF, Evans SL, Wang SB, Doyle KM, Crainiceanu CM, et al. (2009). Mercury induces an unopposed inflammatory response in human peripheral blood mononuclear cells in vitro. Environ Health Perspect 117: 1932-1938.
65. Ghiso J, Calero M, Matsubara E, Governale S, Chuba J, Beavis R, et al. (1997). Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett 408: 105-108.
66. Goodrich JM, Basu N, Franzblau A, Dolinoy DC, (2013). Mercury biomarkers and DNA methylation among Michigan dental professionals. Environ Mol Mutagen 54: 195-203.
67. Gorina R, Font-Nieves M, Marquez-Kisinousky L, Santalucia T, Planas AM, (2011). Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFkappaB signaling, MAPK, and Jak1/Stat1 pathways. Glia 59: 242-255.
68. Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, et al. (2004). New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 1033: 290-315.
69. Guo TL, Mudzinski SP, Lawrence DA, (1996). The heavy metal lead modulates the expression of both TNF-alpha and TNF-alpha receptors in lipopolysaccharide-activated human peripheral blood mononuclear cells. J Leukoc Biol 59: 932-939.
70. de Haan JJ, Smeets MB, Pasterkamp G, Arslan F, (2013). Danger signals in the initiation of the inflammatory response after myocardial infarction. Mediators Inflamm 2013: 206039.
71. Hanna CW, Bloom MS, Robinson WP, Kim D, Parsons PJ, vom Saal FS, et al. (2012). DNA methylation changes in whole blood is associated with exposure to the environmental contaminants, mercury, lead, cadmium and bisphenol A, in women undergoing ovarian stimulation for IVF. Hum Reprod 27: 1401-1410.
72. Hardardottir I, Kunitake ST, Moser AH, Doerrler WT, Rapp JH, Grunfeld C, et al. (1994). Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Invest 94: 1304-1309.
73. He HJ, Wang Y, Le Y, Duan KM, Yan XB, Liao Q, et al. (2012). Surgery upregulates high mobility group box-1 and disrupts the blood-brain barrier causing cognitive dysfunction in aged rats. CNS Neurosci Ther 18: 994-1002.
74. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, et al. (2007). Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178: 829-841.
75. He P, Cheng X, Staufenbiel M, Li R, Shen Y, (2013). Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of beta-secretase in a mouse model of Alzheimer's disease. PLoS ONE 8: e55091.
76. Hill JM, Clement C, Pogue AI, Bhattacharjee S, Zhao Y, Lukiw WJ, (2014). Pathogenic microbes, the microbiome, and Alzheimer's disease (AD). Front Aging Neurosci 6: 127.
77. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. (2008). Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223.
78. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. (2009). Systemic inflammation and disease progression in Alzheimer disease. Neurology 73: 768-774.
79. Holscher C, Li L, (2010). New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol Aging 31: 1495-1502.
80. Howcroft TK, Campisi J, Louis GB, Smith MT, Wise B, Wyss-Coray T, et al. (2013). The role of inflammation in age-related disease. Aging (Albany NY) 5: 84-93.
81. Hua F, Ma J, Ha T, Xia Y, Kelley J, Williams DL, et al. (2007). Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. J Neuroimmunol 190: 101-111.
82. Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Tanaka H, Uematsu S, et al. (2010). Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 171: 258-267.
83. Iraola-Guzman S, Estivill X, Rabionet R, (2011). DNA methylation in neurodegenerative disorders: a missing link between genome and environment? Clin Genet 80: 1-14.
84. Janeway CA Jr, (1989). Pillars article: approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54: 1-13.
85. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982.
86. Ji MH, Yuan HM, Zhang GF, Li XM, Dong L, Li WY, et al. (2013). Changes in plasma and cerebrospinal fluid biomarkers in aged patients with early postoperative cognitive dysfunction following total hip-replacement surgery. J Anesth 27: 236-242.
87. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. (2014). GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nat Med 20: 886-896.
88. Kaut O, Schmitt I, Wullner U, (2012). Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics 13: 87-91.
89. Kim E, Jung YS, Kim H, Kim JS, Park M, Jeong J, et al. (2014). Metabolomic signatures in peripheral blood associated with Alzheimer's disease amyloid-beta-induced neuroinflammation. J Alzheimers Dis 42: 421-433.
90. Knowles TP, Vendruscolo M, Dobson CM, (2014). The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 15: 384-396.
91. Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Chatzigeorgiou S, et al. (2010). Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn Behav Neurol 23: 199-204.
92. Kowalska A, (2003). Amyloid precursor protein gene mutations responsible for early-onset autosomal dominant Alzheimer's disease. Folia Neuropathol 41: 35-40.
93. Lam NY, Rainer TH, Chiu RW, Joynt GM, Lo YM, (2004). Plasma mitochondrial DNA concentrations after trauma. Clin Chem 50: 213-216.
94. Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, et al. (2012). Soluble alpha-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci 32: 10253-10266.
95. Lavieri R, Piccioli P, Carta S, Delfino L, Castellani P, Rubartelli A, (2014). TLR costimulation causes oxidative stress with unbalance of proinflammatory and anti-inflammatory cytokine production. J Immunol 192: 5373-5381.
96. Lee PH, Bang OY, Hwang EM, Lee JS, Joo US, Mook-Jung I, et al. (2005). Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. J Neural Transm 112: 1371-1379.
97. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, Baumgart J, et al. (2012). An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 15: 827-835.
98. Leiendecker J, Hocker J, Meybohm P, Fudickar A, Bein B, (2010). Postoperative neurocognitive function and microembolus detection in patients undergoing neck dissection: a pilot study. Eur J Anaesthesiol 27: 417-424.
99. Leinenga G, Gotz J, (2015). Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer's disease mouse model. Sci Transl Med 7: 278ra33.
100. Li YC, Xi CH, An YF, Dong WH, Zhou M, (2012). Perioperative inflammatory response and protein S-100beta concentrations-relationship with post-operative cognitive dysfunction in elderly patients. Acta Anaesthesiol Scand 56: 595-600.
101. Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS, (2004). Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 279: 49523-49532.
102. Lili X, Zhiyong H, Jianjun S, (2013). A preliminary study of the effects of ulinastatin on early postoperative cognition function in patients undergoing abdominal surgery. Neurosci Lett 541: 15-19.
103. Lin GX, Wang T, Chen MH, Hu ZH, Ouyang W, (2014). Serum high-mobility group box 1 protein correlates with cognitive decline after gastrointestinal surgery. Acta Anaesthesiol Scand 58: 668-674.
104. Linstedt U, Meyer O, Kropp P, Berkau A, Tapp E, Zenz M, (2002). Serum concentration of S-100 protein in assessment of cognitive dysfunction after general anesthesia in different types of surgery. Acta Anaesthesiol Scand 46: 384-389.
105. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM, (2004). Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 25: 419-429.
106. Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T, et al. (2007). Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21: 3904-3916.
107. Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, et al. (2013). TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys. Cell Metab 18: 831-843.
108. Lukiw WJ, (2007). Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 18: 297-300.
109. Lukiw WJ, Alexandrov PN, (2012a). Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain. Mol Neurobiol 46: 11-19.
110. Lukiw WJ, Andreeva TV, Grigorenko AP, Rogaev EI, (2012b). Studying micro RNA function and dysfunction in Alzheimer's disease. Front Genet 3: 327.
111. Margulis L, Chapman MJ, (1998). Endosymbioses: cyclical and permanent in evolution. Trends Microbiol 6: 342-345.
112. Marin I, Kipnis J, (2013). Learning and memory... and the immune system. Learn Mem 20: 601-606.
113. Masters C, (1985). Perspectives on prions. Nature 314: 15-16.
114. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J, (2010). Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging 31: 2025-2037.
115. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J, (2011). Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging 32: 1161-1180.
116. Mathew A, Lindsley TA, Sheridan A, Bhoiwala DL, Hushmendy SF, Yager EJ, et al. (2012). Degraded mitochondrial DNA is a newly identified subtype of the damage associated molecular pattern (DAMP) family and possible trigger of neurodegeneration. J Alzheimers Dis 30: 617-627.
117. Matzinger P, (1994). Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045.
118. Matzinger P, (2002). The danger model: a renewed sense of self. Science 296: 301-305.
119. Maurice T, Lockhart BP, Privat A, (1996). Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706: 181-193.
120. Mazarati A, Maroso M, Iori V, Vezzani A, Carli M, (2011). High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. Exp Neurol 232: 143-148.
121. McAfoose J, Baune BT, (2009). Evidence for a cytokine model of cognitive function. Neurosci Behav Rev 34: 615-619.
122. McClean PL, Holscher C, (2014). Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacol 76 (Pt A): 57-67.
123. McClean PL, Parthsarathy V, Faivre E, Holscher C, (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 31: 6587-6594.
124. Miklossy J, Kis A, Radenovic A, Miller L, Forro L, Martins R, et al. (2006). Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging 27: 228-236.
125. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985.
126. Morris GP, Clark IA, Vissel B, (2014). Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun 2: 135.
127. Mullane K, Williams M, (2013). Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 85: 289-305.
128. Nakane A, Yamada K, Hasegawa S, Mizuki D, Mizuki M, Sasaki S, et al. (1999). Endogenous cytokines during a lethal infection with Listeria monocytogenes in mice. FEMS Microbiol Lett 175: 133-142.
129. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D, (1986). Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 163: 1363-1375.
130. Neva FA, Morgan HR, (1950). Tolerance to the actions of endotoxins of enteric bacilli in patients convalescent from typhoid and paratyphoid fevers. J Lab Clin Med 35: 911-921.
131. Newman S, Stygall J, Hirani S, Shaefi S, Maze M, (2007). Postoperative cognitive dysfunction after noncardiac surgery: a systematic review. Anesthesiology 106: 572-590.
132. Notarachille G, Arnesano F, Calo V, Meleleo D, (2014). Heavy metals toxicity: effect of cadmium ions on amyloid beta protein 1-42. Possible implications for Alzheimer's disease. Biometals 27: 371-388.
133. Ohtake N, Saito M, Eto M, Seki K, (2014). Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex. Regul Pept 190-191: 1-11.
134. Olszowski T, Baranowska-Bosiacka I, Gutowska I, Chlubek D, (2012). Pro-inflammatory properties of cadmium. Acta Biochim Pol 59: 475-482.
135. Oppenheim JJ, Tewary P, de la Rosa G, Yang D, (2007). Alarmins initiate host defense. Adv Exp Med Biol 601: 185-194.
136. Park KM, Yule DI, Bowers WJ, (2008). Tumor necrosis factor-alpha potentiates intraneuronal CA2+ signaling via regulation of the inositol 1,4,5-trisphosphate receptor. J Biol Chem 283: 33069-33079.
137. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
138. Peper RL, Vancampen H, (1995). Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb Pathog 19: 175-183.
139. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al. (2003). Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72: 603-612.
140. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ, (2001). Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 39: 409-413.
141. Pickering M, Cumiskey D, O'Connor JJ, (2005). Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 90: 663-670.
142. Pinti M, Cevenini E, Nasi M, De Biasi S, Salvioli S, Monti D, et al. (2014). Circulating mitochondrial DNA increases with age and is a familiar trait: implications for 'inflamm-aging'. Eur J Immunol 44: 1552-1562.
143. Podlesniy P, Figueiro-Silva J, Llado A, Antonell A, Sanchez-Valle R, Alcolea D, et al. (2013). Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol 74: 655-668.
144. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
145. Prusiner SB, (1984). Some speculations about prions, amyloid, and Alzheimer's disease. N Engl J Med 310: 661-663.
146. Prusiner SB, McKinley MP, Bowman KA, Bolton DC, Bendheim PE, Groth DF, et al. (1983). Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35 (2 Pt 1): 349-358.
147. Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F, et al. (2011). Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69: 819-830.
148. Quistad SD, Stotland A, Barott KL, Smurthwaite CA, Hilton BJ, Grasis JA, et al. (2014). Evolution of TNF-induced apoptosis reveals 550 My of functional conservation. Proc Natl Acad Sci U S A 111: 9567-9572.
149. Raziuddin S, Abdalla RE, el Awad EH, al Janadi M, (1994). Immunoregulatory and proinflammatory cytokine production in visceral and cutaneous leishmaniasis. J Infect Dis 170: 1037-1040.
150. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE, (2009). CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci 29: 11982-11992.
151. Reinsfelt B, Westerlind A, Blennow K, Zetterberg H, Ricksten SE, (2013). Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid beta. Acta Anaesthesiol Scand 57: 82-88.
152. Rohan D, Buggy DJ, Crowley S, Ling FK, Gallagher H, Regan C, et al. (2005). Increased incidence of postoperative cognitive dysfunction 24 h after minor surgery in the elderly. Can J Anaesth 52: 137-142.
153. 3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 62: 229-234.
154. Rosenberger K, Derkow K, Dembny P, Krüger C, Schott E, Lehnardt S, (2014). The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration. J Neuroinflammation 11: 166.
155. Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R, (2007). Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans 35 (Pt 5): 1219-1223.
156. Rubenstein M, Mulholland JH, Jeffery GM, Wolff SM, (1965). Malaria-induced endotoxin tolerance. Proc Soc Exp Biol Med 118: 283-287.
157. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA, (2003). Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 170: 3233-3242.
158. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322-333.
159. Sanchez-Alcazar JA, Schneider E, Martinez MA, Carmona P, Hernandez-Munoz I, Siles E, et al. (2000). Tumor necrosis factor-alpha increases the steady-state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. J Biol Chem 275: 13353-13361.
160. Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, et al. (2012). S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 135 (Pt 11): 3336-3347.
161. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR, (2000). Preclinical' AD revisited: neuropathology of cognitively normal older adults. Neurology 55: 370-376.
162. Schnabel J, (2011). Amyloid: little proteins, big clues. Nature 475: S12-S14.
163. Schulze J, Zierath D, Tanzi P, Cain K, Shibata D, Dressel A, et al. (2013). Severe stroke induces long-lasting alterations of high-mobility group box 1. Stroke 44: 246-248.
164. Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB, et al. (1996). The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci 777: 57-64.
165. Seong SY, Matzinger P, (2004). Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4: 469-478.
166. Shepherd CE, Goyette J, Utter V, Rahimi F, Yang Z, Geczy CL, et al. (2006). Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. Neurobiol Aging 27: 1554-1563.
167. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei EF, Kufe DW, (1988). Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase 1 toxicity and effects on lipid metabolism. J Clin Oncol 6: 344-350.
168. Shichita T, Sakaguchi R, Suzuki M, Yoshimura A, (2012). Post-ischemic inflammation in the brain. Front Immunol 3: 132.
169. Simard JC, Cesaro A, Chapeton-Montes J, Tardif M, Antoine F, Girard D, et al. (2013). S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-kappaB(1). PLoS ONE 8: e72138.
170. Sondheimer N, Zollo O, Van Deerlin V, Trojanowski JQ, (2014). Analysis of cerebrospinal fluid mitochondrial DNA levels in Alzheimer disease. Ann Neurol 75: 458-460.
171. Song JW, Choi BS, (2013). Mercury induced the accumulation of amyloid beta (abeta) in PC12 Cells: the role of production and degradation of abeta. Toxicol Res 29: 235-240.
172. Soontornniyomkij V, Moore DJ, Gouaux B, Soontornniyomkij B, Tatro ET, Umlauf A, et al. (2012). Cerebral beta-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE epsilon4 carriers. AIDS 26: 2327-2335.
173. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. (1988). Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase 1 and pharmacologic study. J Natl Cancer Inst 80: 1039-1044.
174. Stefani M, Dobson CM, (2003). Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) 81: 678-699.
175. Steinmetz J, Christensen KB, Lund T, Lohse N, Rasmussen LS, (2009). Long-term consequences of postoperative cognitive dysfunction. Anesthesiology 110: 548-555.
176. Stellwagen D, Malenka RC, (2006). Synaptic scaling mediated by glial TNF-alpha. Nature 440: 1054-1059.
177. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, et al. (2010). CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11: 155-161.
178. Strand JM, Scheffler K, Bjoras M, Eide L, (2014). The distribution of DNA damage is defined by region-specific susceptibility to DNA damage formation rather than repair differences. DNA Repair (Amst) 18: 44-51.
179. Su X, Wang H, Zhao J, Pan H, Mao L, (2011). Beneficial effects of ethyl pyruvate through inhibiting high-mobility group box 1 expression and TLR4/NF-kappaB pathway after traumatic brain injury in the rat. Mediators Inflamm 2011: 807142.
180. Suter E, Ullman GE, Hoffman RG, (1958). Sensitivity of mice to endotoxin after vaccination with BCG (Bacillus Calmette-Guérin). Proc Soc Exp Biol Med 99: 167-169.
181. Talbot K, Wang HY, (2014). The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. Alzheimers Dement 10 (1 Suppl.): S12-S25.
182. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K, (2003). Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 61: 255-260.
183. Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M, (2010). Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A 107: 20518-20522.
184. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. (2010). Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer's disease. Arch Gen Psychiatry 67: 739-748.
185. Tobinick E, Vega CP, (2006a). The cerebrospinal venous system: anatomy, physiology, and clinical implications. Medgenmed 8: 53.
186. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, DePuy V, (2012). Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs 26: 1051-1070.
187. Tobinick EL, Gross H, Weinberger A, Cohen H, (2006b). TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 8: 25.
188. Tsai NW, Lin TK, Chen SD, Chang WN, Wang HC, Yang TM, et al. (2011). The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke. Clin Chim Acta 412: 476-479.
189. Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, et al. (2012). Tumor necrosis factor-alpha synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation 9: 106.
190. Vanderweyde T, Bednar MM, Forman SA, Wolozin B, (2010). Iatrogenic risk factors for Alzheimer's disease: surgery and anesthesia. J Alzheimers Dis 22 (Suppl. 3): 91-104.
191. Vitkovic L, Bockaert J, Jacque C, (2000a). Inflammatory' cytokines: neuromodulators in normal brain? J Neurochem 74: 457-471.
192. Vitkovic L, Konsman JP, Bockaert J, Dantzer R, Homburger V, Jacque C, (2000b). Cytokine signals propagate through the brain. Mol Psychiatry 5: 604-615.
193. Vollmar P, Kullmann JS, Thilo B, Claussen MC, Rothhammer V, Jacobi H, et al. (2010). Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system. J Immunol 185: 6338-6347.
194. Walko TD 3rd, Bola RA, Hong JD, Au AK, Bell MJ, Kochanek PM, et al. (2014). Cerebrospinal fluid mitochondrial DNA: a novel DAMP in pediatric traumatic brain injury. Shock 41: 499-503.
195. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. (1999a). HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251.
196. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, et al. (1999b). Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126: 389-392.
197. Wang SC, Oelze B, Schumacher A, (2008). Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 3: e2698.
198. Wang QW, Wu JQ, Rowan MJ, Anwyl R, (2005). beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 22: 2827-2832.
199. Wasling P, Daborg J, Riebe I, Andersson M, Portelius E, Blennow K, et al. (2009). Synaptic retrogenesis and amyloid-beta in Alzheimer's disease. J Alzheimers Dis 16: 1-14.
200. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ, (2005). Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18: 459-465.
201. Xie Z, Tanzi RE, (2006). Alzheimer's disease and post-operative cognitive dysfunction. Exp Gerontol 41: 346-359.
202. Xu Z, Dong Y, Wang H, Culley DJ, Marcantonio ER, Crosby G, et al. (2014). Age-dependent postoperative cognitive impairment and Alzheimer-related neuropathology in mice. Sci Rep 4: 3766.
203. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, et al. (2007). Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170: 680-692.
204. Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL, (1989). Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245: 417-420.
205. Yen T, Harrison CA, Devery JM, Leong S, Iismaa SE, Yoshimura T, et al. (1997). Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood 90: 4812-4821.
206. Zhan S, Cai GQ, Zheng A, Wang Y, Jia J, Fang H, et al. (2011). Tumor necrosis factor-alpha regulates the hypocretin system via mRNA degradation and ubiquitination. Biochim Biophys Acta 1812: 565-571.
207. Zhang Q, Itagaki K, Hauser CJ, (2009). Mitochondrial DNA is released by shock and activates neutrophils via p38 MAP-kinase. Shock 34: 55-59.
208. Zhang X, Song W, (2013). The role of APP and BACE1 trafficking in APP processing and amyloid-beta generation. Alzheimers Res Ther 5: 46.
209. Zhao J, O'Connor T, Vassar R, (2011). The contribution of activated astrocytes to Abeta production: implications for Alzheimer's disease pathogenesis. J Neuroinflammation 8: 150.
210. van Zoelen MA, Yang H, Florquin S, Meijers JC, Akira S, Arnold B, et al. (2009). Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31: 280-284.